Tanya Berbasova,
Kleo Pharmaceuticals
Tanya Berbasova
Group Leader, Chemistry and Chemical Biology
Kleo Pharmaceuticals
Be part of a diverse community of innovators committed to the growth and sustainability our bioscience community.
Your source for today’s talent, job opportunities and career development.
New England Edge, powered by MassBio, offers you substantial savings on the products and services you use the most.
Boost your visibility and show your support for Connecticut’s bioscience community.
Dedicated to the growth of a vibrant bioscience ecosystem, our organization connects companies, institutions, entrepreneurs, investors, government, service providers, and other passionate, dedicated people to improve patients’ lives and public health.
Join the National Institutes of Health’s (NIH) National Institute on Aging (NIA) Office of Small Business Research (OSBR) for a webinar on small business funding opportunities to...
Come hear experts in Intellectual Property speak at the What’s New in IP Panel January 30 at UCONN TIP in Farmington. Dr. Craig S. Kenesky, Patent...
Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly...
Pre-Order Registration ends January 31, 2020 – $200.00 Early-Bird Registration ends February 28, 2020 – $250.00 General Registration from March 1, 2020 – $300.00 COMPLIMENTARY TO ALL YALE FACULTY, STAFF, POSTDOCS, AND...
We’ve partnered with MassBio to bring you an even-bigger purchasing program featuring the supplier discounts their members enjoy.
Save big on everything you need, from travel to office products to lab supplies and more.
BioCT keeps policy makers abreast of the latest developments and changing needs of the bioscience community, ensuring policy alignment at the state and federal level.
Bayer and Azitra have announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitra’s...
SpringWorks Therapeutics has entered into a clinical trial collaboration agreement with Allogene Therapeutics.. This agreement will evaluate ALLO-715, Allogene’s investigational anti-B-cell maturation antigen (BCMA) AlloCAR...
Cybrexa Therapeutics has announced CBX-12 (alphalexTM-exatecan) as its new lead development program. CBX-12 is an alphalexTM conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12...